دورية أكاديمية
أعرض في EDS

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review.

التفاصيل البيبلوغرافية
العنوان: Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review.
المؤلفون: Figtree GA; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Electronic address: Gemma.figtree@sydney.edu.au., Vernon ST; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Harmer JA; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia., Gray MP; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia., Arnott C; The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Bachour E; Consumer Representative, Agile Group Switzerland AG, Zug, Switzerland., Barsha G; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia., Brieger D; Department of Cardiology, Concord Repatriation General Hospital, Concord, New South Wales, Australia., Brown A; National Centre for Indigenous Genomics, Australian National University, Canberra, Australian Capitol Territory, Australia; Telethon Kids Institute, Nedlands, Western Australia, Australia., Celermajer DS; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Channon KM; British Heart Foundation Centre of Research Excellence, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Chew NWS; Department of Cardiology, National University Heart Centre, National University Health System, Singapore., Chong JJH; Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia; Westmead Institute for Medical Research, University of Sydney, Westmead, New South Wales, Australia; Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia., Chow CK; Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia; Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia., Cistulli PA; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia; Department of Respiratory & Sleep Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Ellinor PT; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA., Grieve SM; Department of Radiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Imaging and Phenotyping Laboratory, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia., Guzik TJ; Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Department of Internal Medicine and Omicron Medical Genomics Laboratory, Jagiellonian University Medical College, Krakow, Poland., Hagström E; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden., Jenkins A; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia; Diabetes and Vascular Medicine, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Jennings G; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Keech AC; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia., Kott KA; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Kritharides L; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Concord Repatriation General Hospital, Concord, New South Wales, Australia; The ANZAC Research Institute, Concord Repatriation General Hospital, Concord, New South Wales, Australia., Mamas MA; Keele Cardiovascular Research Group, Centre for Prognostic Research, Keele University, Keele, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom., Mehran R; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Meikle PJ; Baker Heart and Diabetes Institute, Melbourne, Vicotria, Australia., Natarajan P; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Negishi K; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia; Department of Cardiology, Nepean Hospital, Kingswood, New South Wales, Australia., O'Sullivan J; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia; Precision Cardiovascular Laboratory, University of Sydney, Camperdown, New South Wales, Australia; Heart Research Institute, University of Sydney, Camperdown, New South Wales, Australia., Patel S; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Heart Research Institute, University of Sydney, Camperdown, New South Wales, Australia., Psaltis PJ; Vascular Research Centre, Heart and Vascular Program, Lifelong Health Theme, SAHMRI, Adelaide, South Australia, Australia; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Department of Cardiology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia, Australia., Redfern J; The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia; Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia., Steg PG; Université de Paris, Assistance Publique-Hôpitaux de Paris, French Alliance for Cardiovascular Trials and INSERM Unité 1148, Paris, France., Sullivan DR; Department of Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Sundström J; The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia; Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Vogel B; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Wilson A; Menzies Centre for Health Policy and Economics, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia., Wong D; Monash Cardiovascular Research Centre, Monash University, Clayton, Victoria, Australia; MonashHeart, Monash Health, Clayton, Victoria, Australia., Bhatt DL; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA., Kovacic JC; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Nicholls SJ; Victorian Heart Institute, Monash University, Clayton, Victoria, Australia.
مؤلفون مشاركون: CRE for CAD Collaborators
المصدر: Journal of the American College of Cardiology [J Am Coll Cardiol] 2023 Sep 26; Vol. 82 (13), pp. 1343-1359.
نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8301365 Publication Model: Print Cited Medium: Internet ISSN: 1558-3597 (Electronic) Linking ISSN: 07351097 NLM ISO Abbreviation: J Am Coll Cardiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [New York, N.Y.] : Elsevier Biomedical, [c1983-
مواضيع طبية MeSH: Coronary Artery Disease*/epidemiology , Myocardial Infarction* , Atherosclerosis*, Humans ; Critical Pathways ; Heart Disease Risk Factors
مستخلص: Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.
Competing Interests: Funding Support and Author Disclosures The Centre for Research Excellence is supported by National Health & Medical Research Council of Australia (grant number GNT1196629). Dr Figtree is funded by a National Health & Medical Research Council Practitioner Fellowship (GNT1135920). Dr Ellinor is supported by grants from the National Institutes of Health (1RO1HL092577, 1R01HL157635, 1R01HL157635), by a grant from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and by a grant from the European Union (MAESTRIA 965286). Dr Psaltis is funded by a National Heart Foundation Level 3 Future Leader Fellowship (106656). Dr Redfern is supported by grants from the National Health & Medical Research Council of Australia (GNT2007946 and GNT1182301). Dr Wilson is supported by grants from the National Health & Medical Research Council of Australia (GNT119600, GNT9100001, GNT1153479). Dr Guzik is funded by the British Heart Foundation and European Research Council (ERC-InflammaTENSION 726318). Dr Arnott has received honoraria from Amgen and AstraZeneca. Dr Brown has received consulting fees from Novartis. Dr Bhatt has received research funding from Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, Cincor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Pharmaceuticals, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer Inc, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, and 89bio; has received royalties from Elsevier; has received consulting fees from Broadview Ventures, Hims, and McKinsey; has received payment or honoraria from the American College of Cardiology, Baim Institute for Clinical Research, Belvoir Publications, Boston Scientific, Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Novartis, Population Health Research Institute, Rutgers University, Canadian Medical and Surgical Knowledge Translation Research Group, Cowen and Company, HMP Global, Journal of the American College of Cardiology, K2P, Level Ex, Medtelligence/ReachMD, MJH Life Sciences, Oakstone CME, Piper Sandler, Slack Publications, WebMD, Wiley, and Society of Cardiovascular Patient Care; has received payment for expert testimony from Arnold and Porter law firm; has received travel or meeting support from the American College of Cardiology, Society of Cardiovascular Patient Care, and American Heart Association; has been named (no income) on a patent application for sotagliflozin, assigned to Brigham and Women’s Hospital, who assigned to Lexicon; serves on a Data Safety Monitoring Board for Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute, Boston Scientific, Cleveland Clinic, Contego Medical, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Novartis, and Population Health Research Institute; has served on an Advisory Board for AngioWave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; has served on the Board of Directors for the American College of Cardiology, AngioWave, Boston VA Research Institute, Bristol Myers Squibb, DRS.LINQ, High Enroll, Society of Cardiovascular Patient Care, and TobeSoft; has stock or stock options with AngioWave, Bristol Myers Squibb, DRS.LINQ, and High Enroll; has financial or other nonfinancial interests in Clinical Cardiology, NCDR-ACTION Registry Steering Committee, Contego Medical, American Heart Association Quality Oversight Committee, VA CART Research and Publications Committee; and is a coinvestigator for Abbott, Biotronik, Boston Scientific, CSI, St Jude Medical, Phillips SpectraWAVE, Svelte, and Vascular Solutions. Dr Brieger has received research grant support from Novartis and has received honoraria from BMS/Pfizer. Dr Chong has received consulting fees from Implicit Bioscience Pty; and has a provisional patent for a cell surface marker signature for arrhythmogenic pluripotent stem cell-derived cardiomyocyte. Dr Cistulli has received research grant support from ResMed and SomnoMed; has received consulting fees from RedMed, SomnoMed, and Signifier Medical Technologies; and has received honoraria from ResMed and SomnoMed. Dr Ellinor has received sponsored research support from Bayer AG and IBM Research; and has served on Advisory Boards or consulted for Bayer AG, MyoKardia, and Novartis. Dr Figtree has received personal fees from Amgen, AstraZeneca, Bayer, CSL, and Janssen; has received grants from Abbott Diagnostic and Sanofi; is a founding director and chief medical officer of Prokardia; has a patent, “Biomarkers and Oxidative Stress,” awarded in the United States in May 2017 (US9638699B2) licensed to Northern Sydney Local Health District; has a patent, “Use of P2X7R Antagonists in Cardiovascular Disease” (PCT/AU2018/050905), licensed to Prokardia; has a patent, “Methods for Treatment and Prevention of Vascular Disease” (PCT/AU2015/000548) licensed to the University of Sydney/Northern Sydney Local Health District; and has a filed provisional patent application, “Methods for Predicting Coronary Artery Disease” (USYD Ref: 2022-009-PRO-0; 2022902660) to the University of Sydney/Northern Sydney Local Health District. Dr Hagström has received research grant support to his institution from Amgen and Pfizer; and has received honoraria from Amgen, AstraZeneca, Bayer, Novo Nordisk, Amarin, and Sanofi. Dr Jenkins has received research grant support from Abbott, Medtronic, and Mylan; and has served on Advisory Boards for Abbott Diabetes Care, Amgen, Insulet, and Medtronic. Dr Keech has received grant support from Abbott, Amgen, and Mylan; has received consulting fees from AstraZeneca, Pfizer, and Sanofi; and has participated as a Data Safety Monitoring Board member for the PROMINENT trial (Kowa Research Institute). Dr Kritharides has received research grant support from Amgen; and has received consulting fees from Seqiris. Dr Meikle has a license agreement with Juvenescence Ltd; and has received consultancy payments (made to Baker Institute) from BCAL Scientific and Juvenescence Ltd. Dr Mehran has received research grant support to her institution from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Amgen, Applied Therapeutics, Arena, AstraZeneca, AtriCure, BAIM, Bayer, Beth Israel Deaconess Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi-Sankyo, Duke University, Element Science, Faraday, Humacyte, Idorsia, Insel Gruppe AG, Magenta, Medtronic, Novartis, OrbusNeich, PhaseBio, Philips, RenalPro, RM Global, Shockwave, and Vivasure Zoll; has received consulting fees from Cine-Med Research; has served on an Advisory Board with all payments made to institution for Abbott, Janssen, Medtronic, and Novartis; and she and/or her spouse has stock or stock options in Applied Therapeutics, ControlRad, Elixir Medical, and Stel. Dr Natarajan has received research grant support from Apple, Amgen, AstraZeneca, Boston Scientific, and Novartis; has received consulting fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genetech/Roche, Invitae, Novartis, and TenSixteen Bio; has served on Advisory Boards for Esperion Therapeutics, geneXwell, and TenSixteen Bio; and holds stock or stock options in TenSixteen Bio and geneXwell. Dr Nicholls has received research grant support from AstraZeneca, Amgen, Anthera, Cerenis, Eli Lilly, Esperion, InfraReDx, LipoScience, The Medicines Company, New Amsterdam Pharma, Novartis, Resverlogix, Roche, and Sanofi-Regeneron; and has received consulting fees from Akcea, Amarin, Anthera, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Omthera, Merck, Resverlogix, Sanofi-Regeneron, Takeda, and Vaxxinity. Dr Psaltis has received consulting fees from Amgen, Esperion Therapeutics, and Novartis; has received speaker honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi; has received meeting travel support from Amgen and AstraZeneca; and has submitted a provisional patent for a method and composition for promoting neovascularization. Dr Sundström has stock or stock options with Anagram Kommunikation AB and Symptoms Europe AB. Dr Steg has received research grant support from Amarin, Bayer, Sanofi, and Servier Laboratories; has received consulting fees from Amgen, AstraZeneca, BMS/Myokardia, Merck, Novo Nordisk, and Regeneron; has served on Steering Committees or Critical Event Committees for Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, and Servier; has received honoraria from AstraZeneca, Novartis, and Novo Nordisk; and has served on Data Safety Monitoring Boards for Servier, Sanofi, and PHRI. Dr Guzik has received research funding from the European Commission (ImmuneHyperCog and BrainGutCVD studies); has served as Editor-in-Chief for Cardiovascular Research; and has served as Board Committee member for the European Society of Cardiology. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
References: J Am Coll Cardiol. 2018 May 15;71(19):2199-2269. (PMID: 29146533)
Am J Prev Cardiol. 2020 Jun 06;2:100028. (PMID: 34327455)
Arterioscler Thromb Vasc Biol. 2022 Mar;42(3):352-361. (PMID: 35045730)
N Engl J Med. 2013 Jul 11;369(2):145-54. (PMID: 23796131)
Thromb J. 2018 Jun 05;16:12. (PMID: 29991926)
Lancet. 2015 Jun 6;385(9984):2264-2271. (PMID: 25748612)
Lancet. 2004 Jan 10;363(9403):157-63. (PMID: 14726171)
Cardiovasc Res. 2021 Jan 21;117(2):367-385. (PMID: 32484892)
Eur Heart J. 2006 Dec;27(24):2962-8. (PMID: 17132649)
Nutr J. 2015 Jan 10;14:6. (PMID: 25577237)
Nat Rev Cardiol. 2022 May;19(5):291-301. (PMID: 34811547)
Circulation. 2012 May 22;125(20):2520-44. (PMID: 22514251)
Arch Intern Med. 2006 Oct 9;166(18):2035-43. (PMID: 17030839)
Trends Endocrinol Metab. 2010 Aug;21(8):496-503. (PMID: 20381374)
Eur Heart J. 2018 Jan 7;39(2):119-177. (PMID: 28886621)
Int Immunopharmacol. 2021 May;94:107466. (PMID: 33636561)
Ann Med. 2009;41(7):522-32. (PMID: 19657769)
Circulation. 2020 Feb 25;141(8):616-623. (PMID: 31707849)
PLoS Med. 2018 Mar 30;15(3):e1002546. (PMID: 29601582)
Heart Lung Circ. 2015 Jul;24(7):696-704. (PMID: 25697383)
Rev Endocr Metab Disord. 2020 Dec;21(4):521-526. (PMID: 32495251)
Med J Aust. 2019 Jul;211(2):65-70. (PMID: 31049990)
J Affect Disord. 2006 Nov;96(1-2):89-93. (PMID: 16857265)
Br J Sports Med. 2021 Apr;55(8):422-432. (PMID: 33355160)
JAMA Cardiol. 2021 Sep 1;6(9):1069-1077. (PMID: 34106216)
J Am Dent Assoc. 2018 Jul;149(7):576-588.e6. (PMID: 29957185)
J Am Heart Assoc. 2019 Nov 5;8(21):e013296. (PMID: 31672080)
Dialogues Clin Neurosci. 2018 Mar;20(1):31-40. (PMID: 29946209)
Angiology. 2011 Jul;62(5):422-9. (PMID: 21421632)
Clin Gastroenterol Hepatol. 2014 Mar;12(3):382-93.e1: quiz e22. (PMID: 23978350)
Circ Res. 2020 Apr 24;126(9):1159-1177. (PMID: 32324503)
J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46. (PMID: 22055990)
Eur J Heart Fail. 2019 Oct;21(10):1169-1186. (PMID: 31129923)
Implement Sci. 2008 Jan 07;3:1. (PMID: 18179688)
J Am Coll Cardiol. 2021 Aug 31;78(9):859-866. (PMID: 34446156)
Cardiovasc Res. 2022 Nov 10;118(14):2880-2902. (PMID: 34609502)
Reprod Biomed Online. 2019 Dec;39(6):1007-1016. (PMID: 31735549)
N Engl J Med. 2006 Oct 12;355(15):1572-82. (PMID: 17035650)
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. (PMID: 12900694)
BMJ. 2002 Nov 23;325(7374):1202. (PMID: 12446535)
BMJ Open. 2016 Aug 30;6(8):e012386. (PMID: 27577588)
Int J Behav Nutr Phys Act. 2020 Jun 20;17(1):78. (PMID: 32563261)
Eur Urol. 2014 May;65(5):968-78. (PMID: 24011423)
Circulation. 2000 Oct 3;102(14):1634-8. (PMID: 11015340)
Eur J Prev Cardiol. 2017 Nov;24(17):1824-1830. (PMID: 28703626)
Can J Cardiol. 2007 Jul;23(9):707-10. (PMID: 17622392)
Circulation. 2006 Dec 12;114(24):2619-26. (PMID: 17116764)
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140. (PMID: 23256914)
Circ Genom Precis Med. 2018 Jul;11(7):e001926. (PMID: 29987111)
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. (PMID: 35379503)
Lancet. 1986 Sep 6;2(8506):533-7. (PMID: 2875280)
Med J Aust. 2009 May 4;190(9):510-1. (PMID: 19413526)
Science. 2017 Feb 24;355(6327):842-847. (PMID: 28104796)
Psychosom Med. 2005 Nov-Dec;67(6):869-78. (PMID: 16314591)
N Engl J Med. 2020 Nov 5;383(19):1838-1847. (PMID: 32865380)
BMC Pregnancy Childbirth. 2015 Jul 04;15:144. (PMID: 26141292)
J Am Acad Dermatol. 2017 Mar;76(3):393-403. (PMID: 28212760)
J Forensic Leg Med. 2015 Jul;33:101-4. (PMID: 26048507)
J Am Coll Cardiol. 2018 Oct 23;72(17):2054-2070. (PMID: 30336830)
Circulation. 2002 Mar 5;105(9):1049-53. (PMID: 11877353)
Lancet. 2021 Mar 20;397(10279):1085-1094. (PMID: 33711294)
Circulation. 2021 Apr 13;143(15):1468-1480. (PMID: 33813836)
J Med Internet Res. 2020 Oct 12;22(10):e23954. (PMID: 33044175)
Circulation. 2020 Feb 25;141(8):624-636. (PMID: 31707832)
JAMA. 2013 Mar 27;309(12):1241-50. (PMID: 23532240)
J Am Coll Cardiol. 2009 Jan 27;53(4):316-22. (PMID: 19161879)
J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90. (PMID: 12475459)
Atherosclerosis. 2018 Sep;276:1-9. (PMID: 30006321)
BMJ Open. 2019 Sep 18;9(9):e028649. (PMID: 31537558)
BJOG. 2016 Jul;123(8):1311-8. (PMID: 26485578)
J Clin Periodontol. 2022 Jun;49 Suppl 24:291-313. (PMID: 34761412)
N Engl J Med. 2017 Jul 13;377(2):111-121. (PMID: 28636844)
Eur Heart J. 2020 Jan 14;41(3):407-477. (PMID: 31504439)
Eur J Prev Cardiol. 2016 Apr;23(6):613-20. (PMID: 26157020)
Curr Atheroscler Rep. 2016 Jan;18(1):1. (PMID: 26710793)
Atherosclerosis. 2013 Oct;230(2):228-34. (PMID: 24075749)
JAMA. 1987 Sep 4;258(9):1183-6. (PMID: 3626001)
J Thorac Dis. 2018 Dec;10(Suppl 34):S4212-S4220. (PMID: 30687537)
J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129. (PMID: 34895950)
Am J Clin Nutr. 2005 Feb;81(2):409-15. (PMID: 15699228)
Atherosclerosis. 2016 Nov;254:59-66. (PMID: 27693879)
J Clin Invest. 2022 Jul 1;132(13):. (PMID: 35617030)
Diabet Med. 2007 Nov;24(11):1199-204. (PMID: 17725630)
Eur Heart J. 2016 Feb 7;37(6):561-7. (PMID: 26392438)
Circulation. 2020 Jan 14;141(2):124-131. (PMID: 31707836)
Cardiovasc Res. 2022 Mar 25;118(5):1188-1204. (PMID: 34229346)
Thorax. 2011 Mar;66(3):213-9. (PMID: 21252389)
Cureus. 2020 Jul 23;12(7):e9349. (PMID: 32742886)
Sleep. 1991 Dec;14(6):540-5. (PMID: 1798888)
Circulation. 2017 May 30;135(22):2091-2101. (PMID: 28223407)
Asia Pac J Clin Nutr. 2008;17(3):370-4. (PMID: 18818155)
Eur Heart J. 2021 Oct 1;42(37):3822-3824. (PMID: 34293105)
Nat Med. 2022 Mar;28(3):583-590. (PMID: 35132265)
N Engl J Med. 2016 Sep 8;375(10):919-31. (PMID: 27571048)
Arch Intern Med. 2004 Jul 26;164(14):1514-8. (PMID: 15277281)
Int J Clin Exp Med. 2015 Feb 15;8(2):2097-107. (PMID: 25932140)
JAMA. 2010 Mar 24;303(12):1159-66. (PMID: 20332401)
Int J Cardiol. 2023 Jan 15;371:432-440. (PMID: 36179904)
Sports Med Open. 2018 Sep 3;4(1):42. (PMID: 30178072)
BMC Oral Health. 2019 May 23;19(1):87. (PMID: 31122214)
Am J Epidemiol. 2009 Sep 1;170(5):615-21. (PMID: 19648170)
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. (PMID: 30423391)
J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46. (PMID: 26112199)
Lancet Public Health. 2022 Mar;7(3):e219-e228. (PMID: 35247352)
Am Heart J. 2013 Oct;166(4):622-628.e1. (PMID: 24093840)
J Am Heart Assoc. 2017 Jul 6;6(7):. (PMID: 28684641)
Nature. 2020 Oct;586(7831):763-768. (PMID: 33057201)
J Cardiopulm Rehabil Prev. 2021 Jul 1;41(4):249-256. (PMID: 33828045)
JAMA Cardiol. 2022 May 1;7(5):521-528. (PMID: 35385050)
Epidemiol Health. 2017 Jun 22;39:e2017026. (PMID: 28728350)
Circulation. 2021 Dec 7;144(23):e472-e487. (PMID: 34724806)
BMC Cardiovasc Disord. 2017 Feb 1;17(1):50. (PMID: 28143450)
Blood. 2015 Jul 2;126(1):9-16. (PMID: 25931582)
PLoS One. 2012;7(2):e30797. (PMID: 22363491)
معلومات مُعتمدة: CH/16/1/32013 United Kingdom BHF_ British Heart Foundation; SP/17/16/33519 United Kingdom BHF_ British Heart Foundation; R01 HL157635 United States HL NHLBI NIH HHS; R01 HL092577 United States HL NHLBI NIH HHS
فهرسة مساهمة: Investigator: Z Ademi; SR Avis; A Chan; O Contreras; CP Coorey; S Fathieh; E Genetzakis; A Gholipour; C Giles; M Hollings; K Hyun; S Kazi; JC Kovacic; M Larance; JA Marathe; C Marquina; A Nelson; HH Ng; E Patrick; K Peter; A Tran; J Yang; D Zhu; C Zwack
Keywords: atherosclerosis; cardiovascular risk; clinical pathway; coronary artery disease; primary prevention; secondary prevention
تواريخ الأحداث: Date Created: 20230920 Date Completed: 20230922 Latest Revision: 20240320
رمز التحديث: 20240320
مُعرف محوري في PubMed: PMC10522922
DOI: 10.1016/j.jacc.2023.06.045
PMID: 37730292
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-3597
DOI:10.1016/j.jacc.2023.06.045